Brain regions that are expected to be earlier affected by AD pathology-linked tau deposition (stage I-IV, MTL, limbic system) showed stronger evidence for monotonic GM volume decline over a sequence of conversions than later stages (stage V/VI, cortical regions). The gene discussed is MAPT; the disease is Alzheimer disease.